ReviewBritish journal of cancer2021
Targeting obesity-related dysfunction in hormonally driven cancers.
Review in British journal of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- The Impact of Bariatric Surgery on the Incidence of Colorectal Cancer in Patients with Obesity-a Systematic Review and Meta-analysis of Registry Data.Obesity surgery · 2023Pooled it
- Systematic Review and Meta-Analysis of the Impact of Bariatric Surgery on Future Cancer Risk.International journal of molecular sciences · 2023Pooled it
- Glucagon-like peptide-1 receptor agonist use and risk of gynecologic cancers: a meta-analysis of multinational real-world cohort studies.Preventive medicine reports · 2026Article
- Hyperinsulinaemia as a cause of obesity and cardiometabolic diseases.Nature reviews. Endocrinology · 2026Review
- A prospective investigation of early-onset colorectal cancer risk factors-pooled analysis of three large-scale European cohorts.British journal of cancer · 2026Article
- Article
- The testobolome in microbial testosterone metabolism and human health.NPJ biofilms and microbiomes · 2026Review
- Metabolic Syndrome Components and Cancer Risk in Normal-Weight Subjects: Systematic Review and Meta-Analysis in over 18 Million Individuals.Journal of clinical medicine · 2026Review
- Population-Level Trends in Lifestyle Factors and Early-Onset Breast, Colorectal, and Uterine Cancers.Cancers · 2026Article
- Evexomostat (SDX-7320), a methionine aminopeptidase type 2 inhibitor, stimulates weight loss and inhibits obesity-accelerated tumor growth.Frontiers in oncology · 2026Article
- Prospective study of circulating metabolomic profiles and breast cancer incidence among predominantly premenopausal women.British journal of cancer · 2025Observational
- Long-Term Breastfeeding: Protective Effects Against Triple-Negative Breast Cancer and the Role of the Breast Microbiota.Pathogens (Basel, Switzerland) · 2025Review
- Cold, Hot, and Lethal-The Tumour Microenvironment and the Immunology of Head and Neck Squamous Cell Carcinoma.International journal of molecular sciences · 2025Review
- Dietary Restrictions and Cancer Prevention: State of the Art.Nutrients · 2025Review
- Integrating the metabolic and molecular circuits in diabetes, obesity and cancer: a comprehensive review.Discover oncology · 2024Review
- Postexercise downregulation ofTranslational cancer research · 2024Article
- Intermittent fasting and the liver: Focus on the Ramadan model.World journal of hepatology · 2024Article
- Review
- The emerging role of GLP-1 receptor agonists in treating or preventing cancer.Cancer drug resistance (Alhambra, Calif.) · 2024Article
- Adipocyte Microenvironment in Ovarian Cancer: A Critical Contributor?International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Obesity is a risk factor for at least 13 different types of cancer, many of which are hormonally driven, and is associated with increased cancer incidence and morbidity. Adult obesity rates are steadily increasing and a subsequent increase in cancer burden is anticipated. Obesity-related dysfunction can contribute to cancer pathogenesis and treatment resistance through various mechanisms, including those mediated by insulin, leptin, adipokine, and aromatase signalling pathways, particularly in women. Furthermore, adiposity-related changes can influence tumour vascularity and inflammation in the tumour microenvironment, which can support tumour development and growth. Trials investigating non-pharmacological approaches to target the mechanisms driving obesity-mediated cancer pathogenesis are emerging and are necessary to better appreciate the interplay between malignancy, adiposity, diet and exercise. Diet, exercise and bariatric surgery are potential strategies to reverse the cancer-promoting effects of obesity; trials of these interventions should be conducted in a scientifically rigorous manner with dose escalation and appropriate selection of tumour phenotypes and have cancer-related clinical and mechanistic endpoints. We are only beginning to understand the mechanisms by which obesity effects cell signalling and systemic factors that contribute to oncogenesis. As the rates of obesity and cancer increase, we must promote the development of non-pharmacological lifestyle trials for the treatment and prevention of malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.